Braidwell’s Dianthus Therapeutics DNTH Stock Holding History

Braidwell’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58M	Sell	594,562 -304,802	-34%	-$26.6M	2.14%	12
2026 Q1	$75.5M	Sell	899,364 -374,571	-29%	-$21.7M	2.52%	9
2025 Q4	$52.5M	Buy	1,273,935 +438,878	+53%	+$17M	1.68%	20
2025 Q3	$32.9M	Buy	+835,057	New	+$21.3M	0.98%	33
2025 Q2	–	Sell	-375,355	Closed	-$6.81M	–	60
2025 Q1	$6.81M	Sell	375,355 -831,234	-69%	-$18.3M	0.24%	55
2024 Q4	$26.3M	Buy	1,206,589 +712,902	+144%	+$18.3M	0.78%	44
2024 Q3	$13.5M	Buy	493,687 +126,836	+35%	+$3.53M	0.38%	57
2024 Q2	$9.49M	Buy	+366,851	New	+$8.82M	0.3%	59

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Braidwell's DNTH Position: Q2 2026 in Review

Braidwell reduced its Dianthus Therapeutics (DNTH) stake by 34% in Q2 2026, selling an estimated $26.6M and leaving 594,562 shares worth $58M. The position accounts for 2.14% of the portfolio, ranked #12.

Braidwell first reported a position in DNTH in Q2 2024 and has held it in 8 quarters since. The position peaked at $75.5M in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Braidwell held 594,562 shares of Dianthus Therapeutics worth $58M as of Q2 2026.
Braidwell sold 304,802 Dianthus Therapeutics shares in Q2 2026, an estimated $26.6M.
Dianthus Therapeutics made up 2.14% of Braidwell's portfolio in Q2 2026, its #12 holding.
Braidwell first reported a position in Dianthus Therapeutics in Q2 2024 and has held it in 8 quarters since.
Braidwell's Dianthus Therapeutics position peaked at $75.5M in Q1 2026.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.